In the journal Science Immunology, researchers from DTU Health Technology and Jacobs University in Bremen have just published their cutting-edge research demonstrating advancement in detection of a certain type of immune cells, called T cells.
For example, in cancer immunotherapy (a therapeutic approach that engage patients own immune cells) characterization of T cells that recognize cancer cells is crucial for tailoring personalized treatment strategies.
To find out how well the immunotherapy is working, scientists and doctors want to check how many tumor-specific T cells a patient has mounted.
The tumor-specific T cells are identified by their specific T cell receptor using a colored reagent called an MHC tetramer.
The MHC proteins of the MHC tetramer reagent were previously difficult to produce due to the inherent instability of the MHC protein, and that used to be a bottleneck in research and diagnosis.
"Whenever a researcher needed MHC tetramers, they had to ask a company to make them, and the process took four to six weeks", explains Prof. Sebastian Springer, Jacobs University Bremen.
TheBusinessResearchCompany published its CAR-T Therapy Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global CAR-T therapy market.
the report covers the CAR-T therapy market’s segments- by target antigen: CD19; CD22; others and by application: acute lymphoblastic leukemia; diffuse large b-cell lymphoma; follicular lymphoma; chronic lymphocytic leukemia; multiple myeloma; and others.Explore Complete Report https://www.thebusinessresearchcompany.com/report/car-t-therapy-market-global-report-2020-covid-19-implications-and-growthCAR-T Therapy Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It covers all the regions, key developed countries and major emerging markets.
Multiple myeloma is a type of white blood cell cancer where the cancer cells accumulate in the bone marrow and surround healthy blood cells.
CAR-T cells are modified to target the multiple myeloma, causing cells to treat the relapsed or refractory multiple myeloma (RRMM).Request to get the sample of this report https://www.thebusinessresearchcompany.com/sample.aspx?id=2808=smpChapters from Table of Content:Chapter 1.
